Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.

CNS drugs - 1 Sept 2020

Menozzi Elisa, Schapira Anthony H V

Abstract excerpt

Mutations in the glucocerebrosidase (GBA1) gene are the most common genetic risk factor for Parkinson disease (PD). Homozygous or compound heterozygous GBA1 mutations cause the lysosomal storage disorder Gaucher disease (GD), characterized by deficient activity of the glucocerebrosidase enzyme (GCase). Both individuals with GD type I and heterozygous carriers of pathogenic variants of GBA1 have an increased risk...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to alpha-Synuclein
Share to Disease Progression
Share to Endoplasmic Reticulum

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genetic Predisposition to Disease

Share to Glucosylceramidase

Share to Parkinson Disease

Share to Protein Folding

Share to Risk Factors

Source

Identifiers

PMID: 32607746
DOI: 10.1007/s40263-020-00746-0

Genes

GBA1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Enhancing the Activity of Glucocerebrosidase as a Treatment for Parkinson Disease.PMID 32607746Read ↗

Glucocerebrosidase as a therapeutic target for Parkinson's disease.Semantic proximity Read ↗

Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicineSemantic proximity Read ↗

Glucocerebrosidase and its relevance to Parkinson diseaseSemantic proximity Read ↗

The role of glucocerebrosidase in Parkinson disease pathogenesis.Semantic proximity Read ↗

Targeting the GBA1 pathway to slow Parkinson disease: Insights into clinical aspects, pathogenic mechanisms and new therapeutic avenues.Semantic proximity Read ↗

Glucocerebrosidase and Parkinson Disease: Molecular, Clinical, and Therapeutic Implications.Semantic proximity Read ↗

GBA Variants and Parkinson Disease: Mechanisms and Treatments.Semantic proximity Read ↗

Glucocerebrosidase, a new player changing the old rules in Lewy body diseases.Semantic proximity Read ↗

Glucocerebrosidase Mutations Cause Mitochondrial and Lysosomal Dysfunction in Parkinson’s Disease: Pathogenesis and Therapeutic ImplicationsSemantic proximity Read ↗

GBA1-associated parkinsonism: new insights and therapeutic opportunitiesSemantic proximity Read ↗

Cross-talks among GBA mutations, glucocerebrosidase, and α-synuclein in GBA-associated Parkinson's disease and their targeted therapeutic approaches: a comprehensive review.Semantic proximity Read ↗

The lysosomal β-glucocerebrosidase strikes mitochondria: implications for Parkinson's therapeutics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.